These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 3103391)
1. Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations. Chase TN; Juncos J; Serrati C; Fabbrini G; Bruno G Adv Neurol; 1987; 45():477-80. PubMed ID: 3103391 [No Abstract] [Full Text] [Related]
2. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Nutt JG; Woodward WR; Anderson JL Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849 [TBL] [Abstract][Full Text] [Related]
3. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222 [TBL] [Abstract][Full Text] [Related]
4. 3-O-methyldopa and the response to levodopa in Parkinson's disease. Nutt JG; Woodward WR; Gancher ST; Merrick D Ann Neurol; 1987 Jun; 21(6):584-8. PubMed ID: 3606046 [TBL] [Abstract][Full Text] [Related]
5. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Marsden CD; Parkes JD Lancet; 1976 Feb; 1(7954):292-6. PubMed ID: 55599 [TBL] [Abstract][Full Text] [Related]
14. [Long-term problems of levodopa therapy in Parkinson disease]. Albani C; Asper R; Baumgartner G Schweiz Med Wochenschr; 1987 Mar; 117(10):347-53. PubMed ID: 3105050 [TBL] [Abstract][Full Text] [Related]
15. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]. García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023 [TBL] [Abstract][Full Text] [Related]